前列地尔与贝那普利联合治疗糖尿病肾病蛋白尿的临床研究

2018-02-12 12:40:41段堂堂
糖尿病新世界 2017年16期

段堂堂

[摘要] 目的 探讨前列地尔与贝那普利联合治疗糖尿病肾病蛋白尿的效果。 方法 选取2015年3月—2017年3月该院收治的糖尿病肾病蛋白尿患者130例,随机分为2组各65例,观察组给予前列地尔联合贝那普利,对照组给予贝那普利,比较疗效。 结果 观察组总有效率为86.2%,明显优于对照组73.8%(P<0.05);治疗后观察组24 h尿蛋白定量(153.8±10.4)mg/24 h、24 h尿微量白蛋白排泄率(2.35±0.33)mg/mol.Cr下降显著优于对照组(P<0.05)。结论糖尿病肾病蛋白尿患者运用前列地尔与贝那普利联合治疗,能有效降低蛋白尿水平,改善肾功能,疗效显著。

[关键词] 前列地尔;贝那普利;糖尿病肾病蛋白尿

[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2017)08(b)-0167-02

Clinical Research on Alprostadil and Benazepril in Treatment of Diabetic Nephropathy Proteinuria

DUAN Tang-tang

Two Cadre Treatment Area, Changchun Central Hospital, Changchun, Jilin Province, 130000 China

[Abstract] Objective To study the effect of alprostadil and benazepril in treatment of diabetic nephropathy proteinuria. Methods 130 cases of patients with alprostadil and benazepril admitted and treated in our department from March 2015 to March 2017 were selected and randomly divided into two groups with 65 cases in each, the observation group were treated with alprostadil and benazepril, while the control group were treated with benazepril, and the curative effect was compared between the two groups. Results The total effective rate in the observation group was obviously better than that in the control group(86.2% vs 73.8%)(P<0.05), and after treatment, the 24 h urine protein quantitation, 24 h micralbuminuria excretion rate in the observation group were respectively (153.8±10.4)mg/24 h and (2.35±0.33)mg/moL.Cr, and the decrease was obviously better than that in the control group(P<0.05). Conclusion The application of alprostadil and benazepril in treatment of diabetic nephropathy proteinuria can effectively reduce the albuminuria level, and improve the renal function, and the curative effect is obvious.

[Key words] Alprostadil; Benazepril; Diabetic nephropathy proteinuria

糖尿病肾病(DN)是糖尿病引起微血管病变而导致的肾小球硬化,是终末期肾病的主要原因。蛋白尿是DN最早期的临床表现,一旦患者出现持续性蛋白尿,肾功能可呈不可逆转势态的快速加重,直至慢性肾功能衰竭终末期。有效预防和治疗糖尿病肾病,减少蛋白尿排泄,对控制和延缓病情发展,提高患者生存质量极为重要。相关研究表明[1],前列地尔与贝那普利具有减少尿蛋白排泄,缓慢和控制糖尿病肾病进展等作用。该文对该院收治的采用前列地尔与贝那普利治疗的65例糖尿病肾病蛋白尿患者进行观察,探讨其对蛋白尿的影响,现报道如下。

1 资料与方法

1.1 一般资料

选取该院收治的糖尿病肾病蛋白尿患者130例为观察对象,均为老年患者,随机将患者分为2组各65例,观察组男36例,女29例,年龄61~77岁,平均(66.8±2.1)岁,病程1~8年,平均(5.1±1.2)年,其中1型糖尿病24例,2型糖尿病41例;对照组男38例,女27例,年齡61~77岁,平均(65.2±1.9)岁,病程1~8年,平均(4.9±1.3)年,其中1型糖尿病21例,2型糖尿病44例。排除严重心肝疾病、泌尿生殖系统感染、高血压及其他免疫性疾病引起的蛋白尿。……

登录APP查看全文